Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
IPO Year:
Exchange: NASDAQ
Website: oncolyticsbiotech.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/6/2022 | $3.00 | Buy | Maxim Group |
SAN DIEGO and CALGARY, AB, Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference, which is taking place September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference, which is taking place September 17-19, 2024 at the InterContinental New York Barclay Hotel in New York, NY. Additional details on t
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns Hopkins Medicine reports that up to 80% of patients are diagnosed at advanced stages, making treatment much more challenging. A recent study in the journal Cell Genomics reveals that key protein biomarkers for early detection have been identified. According to analysts at Research Nester, the pancreatic cancer market is slated to expand by ~18% CAGR between 2024-2035, reaching US$36 billion by 2036. Biotech developers are actively w
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equi
SAN DIEGO and CALGARY, AB, Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA. Additional details on the fireside chat can be found below. Date: Tuesday, August 13, 2024 Time: 8:30 a.m. ET Location: InterContinental Boston, Hutchinson Room Webcast Link: Available by clicking here Company management will also be participating in one-on-one investor
Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 million provides runway through key milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, Aug. 1, 2024 /PRNewswire/ -- Oncolytics B
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024. Conference Call & WebcastDate: Thursday, August 1, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In – International: (646) 357-8785RapidConnect: to join the conference call without operator assi
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 27, 2024 /PRNewswire/ -- USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising rates of cancer, the National Cancer Institute is making calls for change in how cancer clinical research is performed "Because our patients can't wait." According to Spherical Insights, the Global Oncology Drugs Market is projected to grow by 11.5% CAGR through 2033 to US$564.5 billion, highlighting the need for more effective therapies and incentives for those who develop them.
Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024 SAN DIEGO and CALGARY, AB, June 27, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). T
Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO and CALGARY, AB, June 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO dur
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, some are pointing towards increased rates of obesity, among other potential reasons. With the Global Oncology Drugs Market set to grow by 11.5% CAGR through 2033 to US$564.5 billion, according to Spherical Insights, the need for more effective therapies is becoming more apparent. The biotech sector continues to work d
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy.
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO during Dr. Coffey's absence. "On behalf of the Board, I would like to wish Matt a swift recovery. In the interim, the Board and I are highly confident in our tenured executive team's ability to continue executing our mission, achieve our strategic priorities, and drive forward our registration-enabling clinical plans for pela
SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety. It is supported by the US$5M Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award, an innovative program established to accelerate the development of n
One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The second describes pelareorep's ability to induce the expansion of tumor-infiltrating lymphocytes (TILs) across multiple cancers and the correlation between TIL expansion and tumor response. The ASCO annual meeting will take place from May 31 – June 4, 2024, in Chicago, Illinois.
The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for metastatic pancreatic cancer.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is unchanged from the same period last year.
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
SUPPL - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
EFFECT - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
F-X - ONCOLYTICS BIOTECH INC (0001129928) (Subject)
F-10 - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 million provides runway through key milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, Aug. 1, 2024 /PRNewswire/ -- Oncolytics B
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024. Conference Call & WebcastDate: Thursday, August 1, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In – International: (646) 357-8785RapidConnect: to join the conference call without operator assi
Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival data from BRACELET-1 breast cancer study expected in H2 2024 Cash position of $29.6 million provides runway through critical milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31
Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, April 30, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2024. Conference Call & Webcast Date: Thursday, May 9, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In
Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 4, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2023. https://mma.prnewswire.com/media/1762876/4573053/Oncolytics_Biotech_New_Logo.jpg Conference Call & Webcast Date: Thursday, March 7, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Ra
Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2023. https://mma.prnewswire.com/media/1762876/4573053/Oncolytics_Biotech_New_Logo.jpg Conference Call & Webcast Date: Thursday, March 7, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764
Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 4, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2023. Conference Call & WebcastDate: Monday, August 14, 2023Time: 8:30 a.m. ETDial-In – North American Toll-Free: (888) 664-6383Dial-In – International: (416) 764-8650RapidConnect: to join the conference call without operator assistance, please click hereConference ID (if needed): 5411-4798Webcast: please click here A webcast of
Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 4, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2023. Conference Call & WebcastDate: Monday, August 14, 2023Time: 8:30 a.m. ETDial-In – North American Toll-Free: (888) 664-6383Dial-In – International: (416) 764-8650RapidConnect: to join the conference call without operator assistance, please click hereConference ID (if needed): 5411-4798Webcast: please click here A web
Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Guidance on the registration paths for pelareorep in HR+/HER2- metastatic breast and first-line pancreatic cancer expected in H2 2023 $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected cash runway for at least 12 months Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Calif. and CALGARY, AB, May 5, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced recent operational highlights and fina
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023. Conference Call & WebcastDate: Friday, May 5, 2023Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650RapidConnect: to join the conference call without ope
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equi
SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board"). "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics. As we begin preparations to initiate piv
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced the appointment of Jonathan Rigby to its Board of Directors. "Jonathan has successfully built, financed, listed, and led several life science companies across a range of therapeutic areas, and I am thrilled to welcome him to our Board," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "His extensive executive leadership experience, together with his business development and co
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini
Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00
H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00